(Q40505607)

21 September 2017

title

Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma (English)

1 reference

21 September 2017

Ryungsa Kim

1

1 reference

21 September 2017

Manabu Emi

series ordinal

2

1 reference

21 September 2017

Kazuaki Tanabe

series ordinal

3

1 reference

21 September 2017

Tetsuya Toge

series ordinal

4

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

21 September 2017

number of pages

10

1 reference

inferred from page(s)

published in

Cancer

1 reference

21 September 2017

volume

101

1 reference

21 September 2017

issue

10

1 reference

21 September 2017

page(s)

2177-2186

1 reference

Paclitaxel induces apoptosis in human gastric carcinoma cells

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

Chemotherapy: targeting the mitochondrial cell death pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

The biology of neoadjuvant chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Differential expression of cell death regulators in response to thapsigargin and adriamycin in Bcl-2 transfected DU145 prostatic cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Bcl-2 and apoptosis in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Expression of bcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

BCL-2 in prostate cancer: a minireview

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Significance of Apoptosis and Apoptotic-Related Proteins, Bcl-2, and Bax in Primary Breast Cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Irinotecan in the treatment of gastric cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

European health systems and cancer care

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Cytochrome c in the apoptotic and antioxidant cascades

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Effect of overexpression of BCL-2 on cellular oxidative damage, nitric oxide production, antioxidant defenses, and the proteasome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

An association of Bcl-2 phosphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20636

7 January 2021

Identifiers

DOI

10.1002/CNCR.20636

1 reference

21 September 2017

1 reference